Novartis’ Itvisma (onasemnogene) has been approved by the US FDA to treat spinal muscular atrophy (SMA) in children aged two ...
As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector ...
Overall, ESMO 2025 reinforced the growing potential of biomarkers in cancer, with AI integration accelerating adoption. As ...
Go behind the scenes of The participation equation – our call to put people, not just data, at the heart of clinical research ...
Regeneron Pharmaceuticals’ Libtayo (cemiplimab) has received approval from the European Commission for the adjuvant treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback